Genkore Announces Collaboration With A Us-Based Company On In Vivo Gene-Editing Therapy

Genkore, Inc A Korea-Based Biotech Company With Hypercompact Crispr-Cas Tools, Announced That It Has Entered Into A Strategic Research Collaboration With A Us-Based Biopharma Company For The Development Of In Vivo Gene Editing Therapies. This Collaboration Will Utilize Genkore'S Proprietary Crispr-Cas Platform, Target (Tiny Nuclease, Augment Rna-Based Genome Editing Technology). The Target Platform Is Distinct From The Most Popular Genome Editing Technology, Crispr-Cas9, In That The Whole Editing Module Can Be Delivered With A Single Aav Vector. Based On Their Target Platform, Genkore Has Developed Different Modalities Of Editing Tools Including Target-Cut, Target-Adenine Base Editing (Abe), Target-Ai (Gene Activation And Inhibition System). And Target-Free (Gene Knock-In) .This Collaboration Reflects The Strength And Potential Utility Of Target Platform In The Application Of In Vivo Gene-Editing Therapy", Said Yong-Sam Kim, Ceo Of Genkore. "Not Only Will This Collaboration Provide An Opportunity To Validate The Applicability Of Target Platform To In Vivo Therapy, But We Will Also Expand The Utility Of Our Technologies To A Wider Spectrum Of Rare Diseases." The Collaboration Was Built On The Mutual Interest In Forging Transformative Therapeutics For Patients With Rare Diseases.Under The Terms Of The Agreement, Genkore Will Receive Up To 300 Million Usd Including An Upfront, Option Exercise Fees And Milestone Payments Upon Successful Achievement Of R&D And Commercial Milestones Across Two In Vivo Disease Targets. In Addition, Genkore Will Receive Research Funding And Tiered Royalties Up To A Double-Digit Percentage Of Net Sales

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!